- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Trisomy X.
Displaying page 1 of 1.
| EudraCT Number: 2011-001564-21 | Sponsor Protocol Number: GN09CP301 | Start Date*: 2011-09-19 | ||||||||||||||||
| Sponsor Name:NHS Greater Glasgow and Clyde [...] | ||||||||||||||||||
| Full Title: Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study) | ||||||||||||||||||
| Medical condition: Alzheimer's disease Down syndrome | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-004824-19 | Sponsor Protocol Number: ML21206 | Start Date*: 2008-08-08 |
| Sponsor Name:Roche Austria GmbH | ||
| Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study | ||
| Medical condition: Chronic Lymphocytic Leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-001476-22 | Sponsor Protocol Number: 04-30 | Start Date*: 2016-02-16 | |||||||||||
| Sponsor Name:Onconova Therapeutics, Inc. | |||||||||||||
| Full Title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent | |||||||||||||
| Medical condition: Myelodysplastic Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) HR (Completed) PL (Prematurely Ended) SE (Completed) BE (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-013651-29 | Sponsor Protocol Number: AGMT_CLL8/A | Start Date*: 2010-01-13 | |||||||||||
| Sponsor Name:AGMT | |||||||||||||
| Full Title: MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia | |||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) SK (Completed) CZ (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002714-23 | Sponsor Protocol Number: LLC1114 | Start Date*: 2015-01-07 | |||||||||||
| Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
| Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). | |||||||||||||
| Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.